Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Non-Current Liabilities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Total Non-Current Liabilities for 4 consecutive years, with -$301.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 372.82% to -$301.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$301.6 million, a 372.82% decrease, with the full-year FY2024 number at $175.2 million, up 41.34% from a year prior.
  • Total Non-Current Liabilities was -$301.6 million for Q3 2025 at Centessa Pharmaceuticals, down from $147.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $175.2 million in Q4 2024 to a low of -$301.6 million in Q3 2025.
  • A 4-year average of $59.3 million and a median of $109.3 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 165.79% in 2025; the steepest drop was 372.82% in 2025.
  • Centessa Pharmaceuticals' Total Non-Current Liabilities stood at $108.1 million in 2022, then grew by 14.64% to $124.0 million in 2023, then surged by 41.34% to $175.2 million in 2024, then plummeted by 272.12% to -$301.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Total Non-Current Liabilities are -$301.6 million (Q3 2025), $147.2 million (Q2 2025), and $141.6 million (Q1 2025).